EGFR and lung adenocarcinoma: Patient-derived models played a key role in the clinical translation of this important scientific discovery: In the PDX model of EGFR-mutated lung adenocarcinoma, the combination of PI3K/AKT inhibitors and osimertinib might delay or reverse the NE transformation (Quintanal-Villalonga et al., 2021a), while EZH1/2 combined with osimertinib may resensitize the resistant squamous-like tumor to osimertinib (Quintanal-Villalonga et al., 2021b).